How to buy Pacira BioSciences stock (PCRX)

Pacira BioSciences is a drug manufacturers - specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.81 – an increase of 4.37% over the previous week. Pacira BioSciences employs 711 staff and has a trailing 12-month revenue of around $695 million.

Our top picks for where to buy Pacira BioSciences stock

Buy Pacira BioSciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pacira BioSciences stock price (NASDAQ: PCRX)

Use our graph to track the performance of PCRX stocks over time.

Pacira BioSciences shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$19.81
52-week range	$11.16 - $35.95
50-day moving average more info button	$17.76
200-day moving average more info button	$21.58
Wall St. target price	$18.13
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.98

Is it a good time to buy Pacira BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pacira BioSciences price performance over time

Historical closes compared with the close of $19.47 from 2024-12-24

1 week (2024-12-20)	2.58%
1 month (2024-11-27)	17.01%
3 months (2024-09-27)	33.91%
6 months (2024-06-27)	-30.24%

1 year (2023-12-27)	-43.25%
2 years (2022-12-27)	-49.65%
3 years (2021-12-27)	61.4
5 years (2019-12-27)	44.58

Is Pacira BioSciences stock undervalued or overvalued?

Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pacira BioSciences's EBITDA

Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $178 million.

The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.

Pacira BioSciences financials

Revenue TTM	$695 million
Operating margin TTM	13.02%
Gross profit TTM	$393.2 million
Return on assets TTM	4.17%
Return on equity TTM	-11.48%
Profit margin	-13.06%
Book value	$16.24
Market Capitalization more info button	$914.7 million

TTM: trailing 12 months

Pacira BioSciences share dividends

We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.

Pacira BioSciences share price volatility

Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $11.164 up to $35.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 0.818. This would suggest that Pacira BioSciences's shares are less volatile than average (for this exchange).

Pacira BioSciences overview

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc.

Frequently asked questions

What percentage of Pacira BioSciences is owned by insiders or institutions?
Currently 2.149% of Pacira BioSciences shares are held by insiders and 114.63% by institutions. How many people work for Pacira BioSciences?
Latest data suggests 711 work at Pacira BioSciences. When does the fiscal year end for Pacira BioSciences?
Pacira BioSciences's fiscal year ends in December. Where is Pacira BioSciences based?
Pacira BioSciences's address is: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 What is Pacira BioSciences's ISIN number?
Pacira BioSciences's international securities identification number is: US6951271005 What is Pacira BioSciences's CUSIP number?
Pacira BioSciences's Committee on Uniform Securities Identification Procedures number is: 695127100